CN113214230B - 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof - Google Patents
2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof Download PDFInfo
- Publication number
- CN113214230B CN113214230B CN202110684506.9A CN202110684506A CN113214230B CN 113214230 B CN113214230 B CN 113214230B CN 202110684506 A CN202110684506 A CN 202110684506A CN 113214230 B CN113214230 B CN 113214230B
- Authority
- CN
- China
- Prior art keywords
- amino
- pyrazol
- carboxamide
- pyrimidine
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 2-substituted pyrazol Chemical class 0.000 title claims description 49
- 239000000203 mixture Substances 0.000 title abstract description 46
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 107
- 239000003814 drug Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 24
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 15
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 15
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000004631 alopecia areata Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 claims 7
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- VZSBRTQGFZTTMM-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-2-[(1-methylpyrazol-4-yl)amino]pyrimidine-5-carboxamide Chemical compound CN1N=CC(=C1)NC1=NC=C(C(=N1)NCC(C)(C)C)C(=O)N VZSBRTQGFZTTMM-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229940050410 gluconate Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 239000012855 volatile organic compound Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract description 6
- 239000000651 prodrug Substances 0.000 abstract description 6
- 229940002612 prodrug Drugs 0.000 abstract description 6
- 239000012453 solvate Substances 0.000 abstract description 4
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 24
- 235000002639 sodium chloride Nutrition 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 102000042838 JAK family Human genes 0.000 description 21
- 108091082332 JAK family Proteins 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 14
- 239000004012 Tofacitinib Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229960001350 tofacitinib Drugs 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940043355 kinase inhibitor Drugs 0.000 description 9
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010024121 Janus Kinases Proteins 0.000 description 7
- 102000015617 Janus Kinases Human genes 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 238000006911 enzymatic reaction Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 229920003169 water-soluble polymer Polymers 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 101710112793 Tyrosine-protein kinase JAK1 Proteins 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 4
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 238000003674 kinase activity assay Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 2
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010010057 TYK2 Kinase Proteins 0.000 description 2
- 102000015774 TYK2 Kinase Human genes 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2r)-2-methyl-2-[[2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- LURMHCWOXHNATM-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrazol-4-amine Chemical compound COCCN1C=C(N)C=N1 LURMHCWOXHNATM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- JETDYTDZPPMTPP-UHFFFAOYSA-N 2-(methoxymethyl)-n-methylaniline Chemical compound CNC1=CC=CC=C1COC JETDYTDZPPMTPP-UHFFFAOYSA-N 0.000 description 1
- JMUPRKJXQQILFI-UHFFFAOYSA-N 2-(methoxymethyl)benzonitrile Chemical compound COCC1=CC=CC=C1C#N JMUPRKJXQQILFI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YBLLVQWJYBPMEB-UHFFFAOYSA-N 2-aminopyrimidine-5-carboxamide Chemical class NC(=O)C1=CN=C(N)N=C1 YBLLVQWJYBPMEB-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- JRYYVMDEUJQWRO-UHFFFAOYSA-N 2-methylnicotinamide Chemical compound CC1=NC=CC=C1C(N)=O JRYYVMDEUJQWRO-UHFFFAOYSA-N 0.000 description 1
- MQNHKLMHRZYTBZ-UHFFFAOYSA-N 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C(O)=O)=C1 MQNHKLMHRZYTBZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MMRQLDRBAXLMRH-UHFFFAOYSA-N 3-methylpentanenitrile Chemical compound CCC(C)CC#N MMRQLDRBAXLMRH-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 101150058731 STAT5A gene Proteins 0.000 description 1
- 101150063267 STAT5B gene Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100023978 Signal transducer and activator of transcription 2 Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229950008830 decernotinib Drugs 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000005612 glucoheptonate group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- STLSDMWQIGIOTM-UHFFFAOYSA-N n,2-dimethylpyridin-3-amine Chemical compound CNC1=CC=CN=C1C STLSDMWQIGIOTM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention relates to a novel class of compounds, compositions and uses thereof as JAK inhibitors. Specifically, the invention provides a compound (shown as a formula (1)) with strong JAK inhibitory activity, or a stereoisomer, a geometric isomer, a tautomer, a pharmaceutically acceptable salt, a prodrug, a metabolite, an isotope derivative and a solvate thereof, and a pharmaceutical composition containing the compound. The invention also discloses the use of a compound or a pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of an autoimmune disease or cancer.
Description
The application is a divisional application, the application number of the original application is 201811099717.0, the application date is 09/20/2018, and the invention name is '2-substituted pyrazol amino-4-substituted amino-5-pyrimidine carboxamide compounds, compositions and application thereof'.
Technical Field
The invention belongs to the field of chemical medicine, and particularly relates to a compound with JAK kinase inhibitory activity or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, a pharmaceutical composition containing the compound, and application of the compound or the composition in preparation of medicines.
Background
JAK kinases (Janus kinases) and their downstream effector, signal transduction and transcriptional activator proteins form an important cytokine signaling pathway, the JAK-STAT pathway. Researches show that the JAK-STAT pathway can be activated by various cytokines, growth factors and receptors and is involved in processes such as cell proliferation, differentiation, apoptosis, angiogenesis, immunoregulation and the like. JAK kinases are key kinases in the JAK-STAT signaling pathway, which was found to be two decades later, the first JAK kinase inhibitor (tofacitinib) was only approved for the treatment of rheumatoid arthritis in 2012 [ Norman p, selective JAK inhibitors in a course for rhematoid arthritis, expert Opin Investig Drugs,2014,23, 1067-1077].
In a mammal, three members in JAK kinase family, namely JAK1, JAK2, JAK3 and TYK2, consist of more than 1100 amino acids, the relative molecular mass can reach 120000-140000, the homology can reach 40% -70%, the JAK kinase family members can be sequentially divided into 7 homologous structural domains (JH) from the C end to the N end, the JH1 is a kinase region and is highly conserved in the JAK family; JH2 is a kinase-like region or a 'pseudo' kinase region, the pseudo kinase domain is the unique property of JAK protein which is different from other tyrosine proteins, the kinase region has no catalytic activity but has a regulating effect on the activity of JH1, and mutation in the domain can often lead to the enhancement or the reduction of the JAK kinase activity and further lead to the occurrence of certain diseases; JH3-JH4 is an SH2 domain (Src homology 2 domain) containing about 100 amino acid residues that specifically recognize and bind phosphorylated tyrosine residues on ligands; JH5-JH7 are FERM domains that are conserved, primarily regulating JAK binding to receptors. JAK3, a member of the JAK kinase family, structurally contains the kinase domain as described above, and changes in kinase activity are caused by mutations in specific amino acids in different domains.
The JAK-STAT signal pathway is an important intracellular signal transduction pathway in the processes of growth, activation, differentiation, apoptosis and function development of various cells. STATs are a class of cytoplasmic proteins that bind to DNA in the regulatory region of target genes and are downstream substrates of JAKs. The STAT family comprises 7 members such as STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT 6. The interaction between JAKs and STATs plays an important role in Cytokine receptor signaling pathways [ O' Sullivan LA et al, cytokine receptor signaling through the JAK-Stat-Socs pathway in disease, mol Immunol,2007, 44. Cytokine receptors on cell surfaces, when bound to their respective cytokine ligands, cause dimerization of the receptor molecules, allowing JAK kinases coupled to the receptors to approach each other and become activated by interactive tyrosine phosphorylation. The JAK-STAT signaling pathway is a signaling pathway stimulated by multiple cytokine receptors, JAK kinases mediate signaling of most cytokines in cells, such as Interleukins (ILs), interferons (IFNs), erythropoietin (EPO), granulocyte and Macrophage Colony Stimulating Factor (GMCSF), somatotropin (GH), prolactin (PRL), thrombopoietin (TPO), platelet derived factor (PDGF), and Epidermal Growth Factor (EGF), among others, and different receptors activate different subtypes of JAK kinases to exhibit differential biological functions [ Pesu m.et al, therapeutic targeting of Janus kinases, immunol Rev,2008,223 132-142].
JAK1 and JAK2 are expressed in each tissue cell of the human body, and JAK3 is mainly expressed in each hematopoietic tissue cell, and mainly exists in bone marrow cells, thymocytes, NK cells, activated B lymphocytes, and T lymphocytes. Deletions of JAK1 and JAK2, etc., cause lethal damage to humans, whereas JAK3 deletion avoids toxic adverse effects that damage other tissue cells [ Yamaoka k., et al, JAK3 connective tissue diagnostic-cell cytokine production and survival, blood,2005, 106. Based on the functional characteristics and special tissue distribution of each subtype in the JAK kinase family, JAK3 has become a popular target for treating autoimmune diseases, and more clinical researches focus on blocking the JAK3 signal transduction path for treating rheumatoid arthritis. In 2012, the selective JAK3 inhibitor Tofacitinib passed clinical trials and was approved for the treatment of rheumatoid arthritis.
Tofacitinib (CP 690550) is a pyrrolopyrimidine selective JAK3 kinase inhibitor developed by Pfizer company, and has JAK3 inhibitory activity (IC) 50 =1 nmol/L) is JAK2 (IC) 50 20 times of =20 nmol/L) and JAK1 (IC) 50 =112 nmol/L). The research on the stereochemistry of Tofacitinib shows that the chiral structure of Tofacitinib determines that Tofacitinib can be specifically bound to JAK3 molecules, so that JAK3 phosphorylation is inhibited, STAT phosphorylation is further hindered, and the synthesis of downstream inflammatory cytokines is inhibited. Tofacitinib shows good clinical curative effect in clinical research, in the clinical trial research of rheumatoid arthritis, a 5mg or 10mg Tofacitinib measuring group and an equivalent placebo group show obvious statistical difference in comparison, but Tofacitinib is found to be related to serious infection risk increase in the clinical trial research, and the long-term safety of Tofacitinib is required to be further researched.
The JAK-STAT signal pathway plays an important role in the cell differentiation and proliferation processes, and the change of the JAK activity also causes the change of the signal transmission of the pathway, thereby influencing the cell function. Based on the key role of JAK kinase in JAK-STAT signal transmission and the specific histocyte distribution of JAK3 kinase, JAK3 becomes a good therapeutic target for diseases such as rheumatoid arthritis.
At present, JAK3 inhibitors are mainly used for treating patients with moderate and severe rheumatoid arthritis, and the drugs show good treatment effect and good safety in treatment, but the long-term safety of the drugs still needs to be further improved. During the clinical research process of Tofacitinib, certain adverse reactions including infection, tuberculosis, tumor, liver injury and the like can be caused after the medicament is used, so that the key problems to be solved urgently in the research field are to improve the drug effect of the JAK3 inhibitor and reduce toxic and side effects.
The JAK kinase has high ATP binding site homology of several subtypes and small structural difference, which is an important reason for low selectivity of JAK inhibitors. There is still room for improvement in therapeutic effect, selectivity and safety of a series of JAK kinase inhibitors disclosed so far, and there is still a need to develop JAK inhibitors with better drug effect and better safety. Although a high-selectivity JAK inhibitor is the focus of research in the field at present, in view of the fact that each member of a JAK kinase family is closely related to JAK-STAT signal transmission, the pan-JAK inhibitor can remarkably improve the drug effect and greatly reduce the drug dosage, thereby achieving the purpose of controlling toxic and side effects. In addition, the significant improvement of the drug efficacy will contribute to the development of anti-inflammatory drugs for transdermal administration. The research and development of the medicines provide a new way for treating autoimmune diseases such as psoriasis, leucoderma, dermatitis, alopecia areata, rheumatoid arthritis, colitis, multiple sclerosis, systemic lupus erythematosus, crohn's disease and the like, and cancers such as leukemia, lymphoma, multiple myeloma and the like. The compounds of the present invention exhibit excellent biological activity as JAK kinase inhibitors.
Disclosure of Invention
The invention provides a 2- (1-substituted pyrazol-4-) amino-4-substituted amino-5-pyrimidine carboxamide compound and application thereof in preparing a medicament for treating or preventing diseases caused by tyrosine kinases (such as JAK1, JAK2, JAK3 and TYK 2) or variants thereof.
The present invention provides a compound, or an isomer, solvate or pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, in the form of a pharmaceutical composition in its effective polymorphic form, the compound having the structural formula (I):
wherein,
R 1 is composed ofn 1 Is 0 to 1,n 2 Is 0 to 1,n 3 Is a mixture of a water-soluble polymer and a water-soluble polymer, wherein the water-soluble polymer is 0-5%,
A compound of formula (I) wherein R is a substituent 3 Comprises the following steps:
a) H, a hydroxyl group, a cyano group,
b)C 1 -C 5 a linear or branched alkyl group,
c)C 3 -C 8 cycloalkyl, more preferably C 3 -C 7 A cycloalkyl group,
d)C 1 -C 5 a straight-chain or branched alkoxy group, a linear or branched alkoxy group,
e)C 1 -C 5 a straight-chain or branched alkylthio group having a structure,
f) 5-7 membered heterocyclic ring, preferably said 5-7 membered heterocyclic ring contains 1-2 heteroatoms selected from O and/or N and/or S, and when N is the heteroatom, H or C is attached to N 1 -C 4 Alkyl radical, C 1 -C 3 Acyl, preferably acetyl, trifluoroacetyl, propionyl, N-diformyl, when the heteroatom is S, 0 to 2 oxygen atoms are attached to S,
g) Substituted or unsubstituted five-membered aryl or heteroaryl, preferably, the structural formula of the substituted or unsubstituted five-membered aryl or heteroaryl isWherein: j is a unit of 1 And/or J 2 And/or J 3 And/or J 4 C, N, S, O; r 9 Is C 1 -C 3 A linear or branched alkyl group,
or the structural formula of the substituted or unsubstituted five-membered aryl or heteroaryl is shown asOrWherein:
J 1 、J 2 、J 3 、J 4 each independently is C, N, S, O,
R 20 、R 21 each independently is C 1 -C 3 A straight-chain or branched alkyl group,
h) Substituted or unsubstituted six-membered aryl or heteroaryl,
preferably, the substituted or unsubstituted six-membered aryl or heteroaryl has the structural formulaWherein:
Q 1 、Q 2 、Q 3 、Q 4 、Q 5 is N or C;
R 10 and/or R 11 And/or R 12 Comprises the following steps:
1)-F、-Cl、-Br、-CF 3 、-OCF 3 a cyano group;
2) -NR 'R ", R', R" being H, C 1 -C 3 Alkyl groups of (a);
3)C 1 -C 3 alkyl radical, C 2 -C 5 Alkynyl, C 3 -C 5 A cycloalkyl group;
4)SO 2 R 13 wherein R is 13 Is H, C 1 -C 3 An alkyl group;
Or a branched alkyl group;
or the structural formula of the substituted or unsubstituted six-membered aryl or heteroaryl is shown asWherein:
Q 1 、Q 2 、Q 3 、Q 4 、Q 5 is N or C;
R 17 、R 18 each independently is:
a)-H,
b)-F、-Cl、-Br、-CF 3 、-OCF 3 a cyano group,
c) -NR 'R ", R', R" being H, C 1 -C 3 The alkyl group (b) of (a),
d)C 1 -C 3 alkyl radical, C 2 -C 5 Alkynyl, C 2 -C 5 Alkenyl radical, C 3 -C 5 A cycloalkyl group,
e)SO 2 R 13 wherein R is 13 Is H, C 1 -C 3 An alkyl group, a carboxyl group,
h)-(CH 2 ) t -R 19 t is 1-2, R 19 Is C 3 -C 5 A cycloalkyl group;
i) A five-or six-membered ring containing 0-3 heteroatoms or a five-or six-membered ring containing 1-3 heteroatoms, preferably selected from:the substituent R in the formula (I) 6 Comprises the following steps:
a) H and a hydroxyl group, wherein the hydroxyl group,
b) -NR 'R ", R' and R" being H, C 1 -C 3 The alkyl group of (a) is,
c)C 1 -C 5 a linear or branched alkyl group,
d)C 3 -C 8 a cycloalkyl group,
e)C 1 -C 5 a straight-chain or branched alkoxy group, or a linear or branched alkoxy group,
f)C 1 -C 5 a straight-chain or branched alkylthio group having a structure,
g) A heterocyclic group, preferably a five-or six-membered oxygen-and/or nitrogen-containing heterocyclic group, such as
The present invention provides a compound, or an isomer, solvate or pharmaceutically acceptable salt thereof, having the structural formula (I):
wherein,
R 1 is composed ofn 1 Is 0 to 2,n 2 Is 0 to 1,n 3 Is a mixture of a water-soluble polymer and a water-soluble polymer, wherein the water-soluble polymer is 0-5%,
R 3 is R 22 Substituted C 1 -C 3 Alkoxy or R 22 Substituted C 1 -C 3 Alkylthio radical, R 22 Is hydroxy, C 1 -C 3 Alkoxy radical, C 1 -C 3 Alkylthio, -NR' R ", hydroxy-substituted C 1 -C 3 Alkoxy, amino substituted C 1 -C 3 Alkoxy, hydroxy-substituted C 1 -C 3 Alkylthio, amino substituted C 1 -C 3 Alkylthio, wherein R ', R' are H, C 1 -C 3 Alkyl groups of (a);
R 6 is a) H, a hydroxyl group,
b) -NR 'R ", R' and R" being H, C 1 -C 3 The alkyl group (b) of (a),
c)C 1 -C 5 straight chainOr a branched alkyl group,
d)C 3 -C 8 a cycloalkyl group,
e)C 1 -C 5 a straight-chain or branched alkoxy group, or a linear or branched alkoxy group,
f)C 1 -C 5 a straight or branched alkylthio group, or
It will be clear that the compounds of formula (I), isomers, crystals or prodrugs and pharmaceutically acceptable salts thereof may exist in solvated as well as unsolvated forms. For example, the solvated form may be water soluble. The present invention includes all such solvated and unsolvated forms.
One aspect of the present invention is a pharmaceutical composition comprising a compound of structural formula (I). The composition can be applied to autoimmune diseases such as psoriasis, vitiligo, dermatitis, alopecia areata, rheumatoid arthritis, colitis, multiple sclerosis, systemic lupus erythematosus, crohn's disease and cancers such as leukemia, lymphoma, multiple myeloma, including those with drug resistance by Tofacitinib, pefinitinib, decerntinib or other kinase inhibitors, cancers and the like.
It is a further object of the present invention to provide a method for treating autoimmune diseases and cancer comprising administering to a subject a therapeutically effective amount of a composition comprising a compound of the present invention. Autoimmune diseases, cancers that can be so treated are noted elsewhere herein, including autoimmune diseases, cancers, etc. that are resistant to treatment with Tofacitinib, pefitinib, roxolitinib, decernotinib, or other kinase inhibitors.
One or more other therapies may also be used in combination in the treatment of cancer, including surgery, radiation therapy (e.g., gamma-rays, neutron beam radiation therapy, electron beam radiation therapy, proton therapy, brachytherapy, and systemic radioisotopes, etc.), endocrine therapy, biological response modifiers (e.g., interferons, interleukins, and Tumor Necrosis Factor (TNF)), hyperthermia, cryotherapy, attenuating any adverse effects (e.g., antiemetics), and other therapeutic agents.
The invention also includes the use of a compound of the invention, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of diseases such as ocular fundus disease, dry eye, psoriasis, rheumatoid arthritis, skin rash, eczema, alopecia areata, atheroma, pulmonary fibrosis, liver fibrosis, myelofibrosis, inflammatory bowel disease and autoimmune diseases, as well as tumors, including those diseases which develop resistance to one or more other therapeutic agents, as noted elsewhere herein. The compounds of the invention are also useful in medicine for alleviating or preventing disease by inhibiting one or more kinases (e.g., JAK1, JAK2, JAK3, TYK 2).
The invention also provides a method for preparing the corresponding compound, which can be prepared by the following method. The synthetic route for the series (I) of compounds is shown below:
reagents and reaction conditions (a) DIEA, THF; (b) s-BuOH, TFA.
Detailed Description
The synthesis method of the intermediate is as follows:
preparation of intermediate 1- (2-methoxyethyl) -1H-pyrazol-4-amine:
66%。 1 H NMR(400MHz,DMSO-d 6 )δ8.85(s,1H),8.27(s,1H),4.35(t,J=5.1Hz,2H),3.73(t,J=5.2Hz,2H),3.24(s,3H).LCMS:m/z=172.1(M+H) + .
preparation of intermediate 2- [2- (methylthio) ethyl ] -1H-pyrazol-4-amine:
column chromatography (petroleum ether: ethyl acetate = 4) gave 180mg of a yellow oil in 54% yield. LCMS M/z =188.0 (M + H) + .
TABLE 1 Synthesis of intermediates 3-22 (reference Process for Synthesis of intermediates 1 or 2)
Preparation of intermediate 23-cyclopropyl-1H-pyrazol-4-amine:
cyclopropyl boronic acid (320mg, 3.72mmol), copper acetate (326mg, 1.79mmol), pyridine (144mg, 1.82mmol) and sodium carbonate (432mg, 4.08mmol) were added, and the mixture was reacted at 70 ℃ under an argon atmosphere for 4 hours. The reaction solution was concentrated by column chromatography (petroleum ether: ethyl acetate =4 = 1) to obtain 110mg of a yellow oil in 41% yield. LCMS M/z =154.1 (M + H) + .
To a mixed solution of ethyl acetate (2 mL), raney nickel (15 mg) was added and the reaction was carried out under hydrogen atmosphere for 3 hours. The mixture was filtered through celite, and the filtrate was evaporated to dryness to give 90mg of a brown oil with a yield of 90%. 1 H NMR(400MHz,DMSO-d 6 )δ7.02(s,1H),6.86(s,1H),3.89–3.61(m,2H),3.50–3.45(m,1H),0.91–0.73(m,4H).LCMS:m/z=124.1(M+H) + .
Preparation of intermediate 24- (6-methoxyhexyl) -1H-pyrazol-4-amine:
hexane (864mg, 3.54mmol) was reacted at 80 ℃ for 3 hours. The reaction solution was poured into ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered to dryness and subjected to column chromatography (petroleum ether: ethyl acetate = 5). LCMS M/z =276.0 (M + H) + .
The reaction mixture was quenched with saturated brine, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered to dryness, and subjected to reverse phase column chromatography (petroleum ether: ethyl acetate = 5. LCMS M/z =228.1 (M + H) + .
Raney nickel (25 mg) was reacted under hydrogen atmosphere for 3 hours. The mixture was filtered through celite, and the filtrate was evaporated to dryness to give 190mg of a brown oil with a yield of 95%. LCMS M/z =198.2 (M + H) + .
Preparation of intermediate 25-methyl-1-pentylamine:
3-Methylpentanenitrile (400mg, 4.11mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) at 0 deg.C with argon
TABLE 2 Synthesis of intermediates 26 to 28 (Synthesis of reference intermediate 29)
Preparation of intermediate 29 2- (methoxymethyl) phenyl ] methylamine:
step 1): preparation of 2- (methoxymethyl) benzonitrile:
step 2): preparation of [2- (methoxymethyl) phenyl ] methylamine:
Preparation of intermediate 30 (2-methylpyridin-3-yl) methylamine:
2-Methylnicotinamide (200mg, 1.47mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) and argon was applied at 0 deg.C
Preparation of intermediate 31[3- (dimethylcarbamoyl) benzyl ] amino hydrochloride:
3- (((tert-butoxycarbonyl) amino) methyl) benzoic acid (400mg, 1.59mmol) was dissolved in tetrahydrofuran
The reaction solution was obtained in 263mg as a white solid with a yield of 77%. LCMS M/z =179.1 (M + H) + .
Examples
Example 1 preparation of 4-benzylamino-2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide:
step 1): preparation of 2-chloro-4- (benzylamino) pyrimidine-5-carboxamide:
step 2): preparation of 4-benzylamino-2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide:
example 2 preparation of 4- [ (5-hydroxypentyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide:
7.96(s,1H),7.68(s,1H),3.87(s,3H),3.60–3.47(m,2H),3.39(t,J=6.3Hz,2H),1.69–1.54(m,2H),1.51–1.40(m,2H),1.40–1.29(m,2H).LCMS:m/z=320.2(M+H) + .
example 3 preparation of 4- [ (5-methoxypentyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide:
step 1), step 2) in the same manner as in example 8
MHz,DMSO-d 6 +DCl/D 2 O)δ8.69(s,1H),8.02(s,1H),7.76(s,1H),3.90(s,3H),3.53(t,J=6.7Hz,2H),3.31(t,J=6.1Hz,2H),3.20(s,3H),1.69–1.57(m,2H),1.57–1.44(m,2H),1.44–1.30(m,2H).LCMS:m/z=334.2(M+H) + .
Example 4 preparation of 4- [ (3-hydroxy-3-methylbutyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide:
Extraction with ethyl ester, washing with saturated brine, drying over anhydrous sodium sulfate, filtration to dryness, thin layer chromatography (dichloromethane: methanol = 10). 1 H NMR(400MHz,DMSO-d 6 +DCl/D 2 O)δ8.57(s,1H),8.01(s,1H),7.62(s,1H),3.78(s,3H),3.63–3.47(m,2H),1.71–1.56(m,2H),1.08(s,6H).LCMS:m/z=320.2(M+H) + .
Example 5 preparation of 4- [ [ (1-acetylpiperidin-4-yl) methyl ] amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide:
saturated brine (40 mL), stirred for 15 min, filtered and the filter cake washed with petroleum ether to give 150mg of a white solid in 79% yield. LCMS M/z =370.2 (M + H) + .
Triethylamine (160mg, 1.58mmol) was added thereto, and after stirring for 2 minutes, acetyl chloride (63mg, 0.80mmol) was added dropwise, and the reaction was carried out at 25 ℃ for 2 hours. The reaction solution was concentrated and subjected to thin layer chromatography (dichloromethane: methanol =10 = 1) to obtain 30mg of a white solid in a two-step yield of 30%. 1 H NMR(400MHz,DMSO-d 6 +DCl/D 2 O)δ8.72(s,1H),8.02(s,1H),7.75(s,1H),4.47–4.25(m,1H),3.90(s,3H),3.48(d,J=6.7Hz,2H),3.17–3.02(m,1H),2.54(s,3H),2.13–2.07(m,2H),2.04–1.89(m,1H),1.80–1.63(m,2H),1.32–1.05(m,2H).LCMS:m/z=373.2(M+H) + .
Example 6 preparation of 4- [ [2- (1-acetylpiperidin-4-yl) ethyl ] amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide:
after stirring for 15 min, filtration was carried out and the filter cake was washed with petroleum ether to give 270mg of a white solid in 68% yield. LCMS M/z =384.2 (M + H) + .
Acid (0.1 mL) was added and the reaction was stopped at 100 ℃ for 2 hours. The reaction was concentrated, the solid filtered and washed with acetonitrile to give 170mg of a white solid in 54% yield. LCMS M/z =445.3 (M + H) + .
(176mg, 1.36mmol), and after stirring for 2 minutes, acetyl chloride (69mg, 0.88mmol) was added dropwise, and the reaction was carried out at 25 ℃ for 2 hours. The reaction solution was concentrated and subjected to thin layer chromatography (dichloromethane: methanol =10 = 1) to obtain 10mg of a pale yellow solid in a two-step yield of 7%. 1 H NMR(400MHz,DMSO-d 6 +DCl/D 2 O)δ8.58(s,1H),7.90(s,1H),7.63(s,1H),4.34–4.08(m,1H),3.79(s,3H),3.77–3.64(m,1H),3.53–3.37(m,2H),3.04–2.83(m,1H),2.45–2.38(m,1H),1.98(s,3H),1.69–1.55(m,2H),1.52–1.37(m,3H),1.11–0.79(m,2H).LCMS:m/z=387.2(M+H) + .
Synthesis of the remaining examples
Synthesis of subsequent specific examples the synthesis of the corresponding intermediate a and the target compound B was carried out according to the synthetic route shown below in a similar manner to example 1 using starting materials with different substituents, as shown in tables 3 and 4 below.
Reaction conditions are as follows: 1) R is 1 CH 2 NH 2 ,DIEA,THF,25℃,2~16h;2)TFA,s-BuOH,60~100℃,2~16h.
TABLE 3 structures and characterizations of intermediate Compound A and target Compound B of examples 7-28
TABLE 4 structures and characterizations of intermediate Compound A and target Compound B of examples 29-35
EXAMPLE 1 assay for inhibition of JAK1, JAK2, JAK3, TYK2 kinase Activity by Compounds of the invention
In the in vitro assembled enzymatic reaction, compounds with different concentrations are added to detect the inhibition of the specific enzymatic reaction by the compounds, and the specific test method is as follows:
TABLE 5 instruments, materials and reagents for testing
Second, testing method
The following experimental conditions are described in the appendix, taking JAK3 as an example, and JAK1, JAK2, JAK3 and TYK2 as specific examples.
1. Preparing a reagent:
preparation of EDTA (0.5M pH8.0) solution by accurately weighing 14.612g of EDTA powder, adding ultrapure water, and diluting to 100mL (if insoluble, heating to 37 deg.C, adjusting pH to 8.0 with 1N NaOH solution)
1 × Kinase Assay Buffer: into a reagent bottle were added 25mL of HEPES solution (1M), 190.175mg of EGTA, and 5mL of MgCl 2 The solution (1M), 1mL DTT, 50. Mu.L Tween-20, and ultrapure water were added to make a volume of 500mL (pH adjusted to 7.5).
1 XDeprotection Buffer 1mL 10 XDeprotection Buffer was added to 9mL water and mixed.
4 × stop solution: 0.8mL of the above EDTA (0.5M, pH 8.0) solution, 1mL of 10 × Detection Buffer, and 8.2mL of ultrapure water were mixed together.
4 XJAK 3 Kinase solution the Kinase stock solution was diluted with 1 XKinase Assay Buffer to a concentration of 0.36nM, mixed well and stored on ice.
4 × substrate solution: substrate ULight was diluted with 1 × Kinase Assay Buffer TM -Labeled JAK-1 (Tyr 1023) Peptide stock solution to 200nM and mixed well.
4 × ATP solution: the ATP stock was diluted with 1 XKinase Assay Buffer to a concentration of 40. Mu.M and mixed well.
4 × detection solution: the Detection antibody Europian-anti-phosphorus-tyrosine antibody (PT 66) was diluted to a concentration of 8nM with 1 XDedetection Buffer and mixed well.
2 × substrate/ATP mixture: the 4 Xsubstrate solution and 600. Mu.l of 4 XATP solution were mixed in equal amounts (prepared before use).
2. Experimental procedure
1) The dilution of the compound(s) is carried out,
in a 96-well plate, compounds were diluted 3-fold in DMSO solution to form 11 gradients, and another pure DMSO solution served as a positive control; a new 96-well plate was prepared, and the solution was diluted 25-fold with ultrapure water (DMSO concentration: 4%)
2) Rotating Compounds to 384 well plates
The compound solution diluted with ultrapure water in the above 96-well plate was transferred to the corresponding well of the 384-well plate according to a standard 2-well rotary plate.
3) Add 4 × kinase solution: mu.l of the above 4 Xkinase solution was added to the corresponding reaction well of 384-well plate by using a discharge gun, and pre-reacted at room temperature for 5 minutes.
4) Add 2 Xsubstrate/ATP mix 5. Mu.l of the above 2 Xsubstrate/ATP mix to the corresponding reaction well of a 384 well plate using a discharge gun.
5) Negative control: a negative control well was set in a 384-well plate to which 2.5. Mu.l/well 4 Xsubstrate, 2.5. Mu.l 4 Xenzyme solution, 2.5. Mu.l 1 XKinase Assay Buffer and 2.5. Mu.l ultrapure water containing 4% DMSO were added.
6) And (4) centrifuging, mixing uniformly, and reacting for 60min at room temperature in the dark.
7) Termination of the enzymatic reaction:
mu.l of the 4 Xstop buffer was pipetted into the corresponding well of 384-well plate, centrifuged and mixed, and reacted at room temperature for 5 minutes.
8) And (3) color development reaction:
5. Mu.l of the 4 × detection solution was pipetted into the mesopores of 384-well plate, centrifuged and mixed, and reacted at room temperature for 60min.
9) The 384-well plate is placed in a plate reader, and the corresponding program detection signal is called.
10 Inhibition ratio and IC 50 And (3) calculating:
well readings =10000 × EU665 value/EU 615 value
Inhibition = [1- (experimental well reading-negative control well reading)/(positive control well reading-negative control well reading) ] + 100%
Inputting the drug concentration and the corresponding inhibition rate into GraphPad Prism5 for processing to calculate the corresponding IC 50 The value is obtained.
Test conditions:
JAK1 kinase activity assay:
JAK1 (final concentration 10 nM); ATP (final concentration 10 μ M); ULight TM -labeled JAK-1 (Tyr 1023) Peptide (final concentration 100 nM); the enzymatic reaction time was 2 hours. The maximum final concentration of the compound was 2.5. Mu.M, and after 3-fold gradient dilution, the minimum final concentration was 0.042nM. The final concentration of DMSO is 1%.
JAK2 kinase activity assay:
JAK2 (final concentration 0.25 nM); ATP (final concentration 5 μ M); ULight TM -labeled JAK-1 (Tyr 1023) Peptide (final concentration 50 nM); the enzymatic reaction time was 1 hour. The maximum final concentration of the compound was 2.5. Mu.M, and after 3-fold gradient dilution, the total concentration was 11 concentrations, and the minimum final concentration was 0.042nM. The final concentration of DMSO is 1%.
JAK3 kinase activity assay:
JAK3 (final concentration 0.36 nM); ATP (final concentration 10 μ M); ULight TM -labeled JAK-1 (Tyr 1023) Peptide (final concentration 50 nM); the enzymatic reaction time was 1 hour. The maximum final concentration of the compound was 2.5. Mu.M, and after 3-fold gradient dilution, the minimum final concentration was 0.042nM. The final concentration of DMSO is 1%.
TYK2 kinase activity assay:
TYK2 (final concentration 8 nM); ATP (final concentration 20 μ M); ULight TM -labeled JAK-1 (Tyr 1023) Peptide (final concentration 100 nM); the enzymatic reaction time was 2 hours. The maximum final concentration of the compound was 2.5. Mu.M, and after 3-fold gradient dilution, the total concentration was 11 concentrations, and the minimum final concentration was 0.042nM. The final concentration of DMSO is 1%.
Table 6 shows the results of measurement of inhibitory activity of some of the compounds of the present invention against tyrosine kinases JAK1, JAK2, JAK3 and TYK 2. IC in the following table 50 The values represent the concentration of compound at which the enzyme inhibits 50% of its maximum, and NT indicates that the corresponding enzyme was not tested.
TABLE 6 results of measurement of JAK1, JAK2, JAK3 and TYK2 tyrosine kinase inhibitory Activity of some of the compounds of the present invention
Experimental example 2 test of inhibitory Activity of Compound of the present invention on mouse spleen cell proliferation
The specific experimental steps are as follows:
1) Compound dilution: a total of 9 concentrations were obtained by 3-fold gradient dilution starting from the highest concentration of 5000nM (the maximum final concentration of drug used in this experiment was 5000nM and the minimum final concentration was 0.76 nM).
2) Taking a culture dish with the diameter of 6 cm, placing a cell filter sieve with the aperture of 70 mu m in the culture dish, and then adding 2mL of HBSS solution into the sieve to infiltrate the bottom of the culture dish;
3) Euthanasia adult Balb/c mice with carbon dioxide, soaking in 75% alcohol for 1 minute, placing into a safety cabinet, cutting a small opening in the middle of the left ventral side of the mice, exposing the abdominal wall, and finding out the spleen;
4) Taking spleen, removing surrounding adipose tissues, putting the spleen on a cell filtering sieve in a culture dish, and properly shearing;
5) Gently grinding the spleen with the flat part at the top end of the syringe piston to obtain a cell suspension;
6) Collecting cell suspension from a culture dish, and slowly adding the cell suspension into a 15ml centrifuge tube containing 5ml of Ficoll-Paque PLUS;
7) Centrifuge at 400g for 30 minutes at room temperature;
8) After the centrifugation is finished, the upper layer is slowly removed by a suction pipe, and then the middle layer, namely spleen cells, is slowly sucked out;
9) Placing the collected spleen cell suspension in another 15ml centrifuge tube, adding 10ml RPMI1640 complete medium, 300g,4 ℃, and centrifuging for 4 minutes;
10 The supernatant was discarded, the cells were resuspended by adding complete medium, and then cell counting was performed. The cell suspension is washed repeatedly according to the ninth step;
11 Cells were transferred to a petri dish (containing 2.5 μ g/mL of concanavalin a) at a cell density of 200 to 500 million/mL for overnight culture;
12 The next day, the cells were transferred to a 15mL centrifuge tube and centrifuged at 300g for 5min;
13 Discarding supernatant, adding 5mL of RPMI1640 complete culture solution, blowing and beating uniformly, mixing 10 μ L of cell suspension and 10 μ L of trypan blue uniformly, counting by using a cell counter, and recording the number of cells and the survival rate.
14 ) the cell suspension was seeded in 96-well plates, with 80. Mu.l of cell suspension per well, at a density of 100000 cells/well;
15 20. Mu.L of the above 5X compound solution diluted with the culture solution was added to each well and mixed well;
16 Add 10. Mu.L CCK-8 reagent per well after 72 hours of incubation, incubate for 2 hours (reaction time can be adjusted according to shade of color);
17 Read its OD value at 450nm on a multifunction plate reader.
18 Data processing:
cell viability (%) = [ (As-Ab)/(Ac-Ab) ] = 100%
As: OD value of the experimental well (cell-containing medium, CCK-8, compound),
ac: OD value of control well (cell-containing medium, CCK-8),
ab: OD of blank wells (medium without cells and compounds, CCK-8),
the values were then imported into Graphpad Prism5 software for curve fitting and IC50 was calculated.
Table 7 shows the results of the test for the inhibitory activity of the compounds of the present invention on the proliferation of mouse splenocytes, wherein A represents IC 50 Less than or equal to 100nM, B representing IC 50 Greater than 100nM but less than or equal to 500nM, C represents IC 50 Greater than 500nM but less than or equal to 1000nM, D representing IC 50 Greater than 1000nM.
TABLE 7 test results of the inhibitory Activity of the Compounds of the present invention on mouse splenocyte proliferation
Use, formulation, administration
Medical application and indications
The biological data provided by the present invention indicate that the compounds of the present invention are useful for the treatment or prevention of diseases caused by tyrosine kinase (JAK 1, JAK2, JAK3, TYK 2) abnormalities. Over one fifth of the compounds of the present invention have been shown to strongly inhibit JAK tyrosine kinase activity, whereas the JAK kinase family is closely related to the development and metastasis of autoimmune diseases and cancer. Thus, the compounds of the present invention are useful in the treatment of autoimmune diseases, including but not limited to: psoriasis, vitiligo, dermatitis, alopecia areata, rheumatoid arthritis, colitis, multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. The compounds of the invention are also useful in the treatment of cancer, including primary and metastatic cancers, including solid tumors. Such cancers include, but are not limited to, non-small cell lung cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, ovarian cancer, cervical cancer, colorectal cancer, melanoma, endometrial cancer, prostate cancer, bladder cancer, leukemia, gastric cancer, liver cancer, gastrointestinal stromal tumors, thyroid cancer, chronic myelogenous leukemia, acute myelogenous leukemia, non-Hodgkin's lymphoma, nasopharyngeal cancer, esophageal cancer, brain tumors, B-cell and T-cell lymphomas, lymphoma, multiple myeloma, biliary sarcoma, cholangiocarcinoma. The compounds of the invention also include the treatment of cancer resistant to one or more other therapeutic methods. The compounds of the present invention may also be used in diseases other than autoimmune diseases and cancer, including but not limited to ocular fundus disease, pulmonary fibrosis, liver fibrosis, etc., associated with JAK1 kinase and/or JAK2 and/or JAK3 kinase. The compounds of the present invention may be administered as a monotherapy or in a combination therapy, in combination with a plurality of the compounds of the present invention or in combination with other drugs outside the present invention.
Pharmaceutical process
The pharmaceutical methods of the invention comprise determining a therapeutically effective amount of a compound of the invention in a subject in need thereof. The "therapeutically effective dose" will vary depending on the stage, progression or severity of the disease. The daily dosage of the compounds and compositions of the present invention will depend upon a variety of factors including the condition being treated, the severity of the condition, the pharmaceutical efficacy of the particular compound employed, the particular composition, the age, body weight, general health, sex and diet, the route and schedule of administration, the rate of metabolism and/or excretion of the compound, the duration of treatment, and the like. In addition, the compounds of the invention can be administered to humans and other animals in dosages and in dosages with a pharmaceutically acceptable carrier. Modes of administration include oral, rectal, parenteral, intracisternal, intravaginal, intraperitoneal, topical (e.g., via transdermal patches, powders, ointments, or drops), sublingual, buccal, or nasal spray, and the like. An effective dose of the compounds of the invention is generally measured as the amount administered per kg of body weight of the patient, preferably from 0.1 to 125 mg/kg body weight, typically from 0.01 to 500 mg/kg body weight. Administration may be one or more times, daily, weekly, every other day or every other day, or on an intermittent schedule. For example, the compound may be administered daily, weekly (e.g., monday), indefinitely or over a period of weeks (e.g., 4-10 weeks). The effective dosage of the compounds of the present invention will vary depending upon the compound employed, the mode of administration, the severity of the disease, the condition being treated and the various physical factors of the patient involved. In most cases, satisfactory therapeutic results will be achieved when the preferred compounds of the invention are administered at a daily dosage of about 0.01 to 500 mg/kg. The preferred dosage is 0.1 to 125 mg/kg, and the more preferred dosage is 1 to 25 mg/kg. Parenteral dosages are generally at an oral dosage level of about 10% to 20%. When the compounds of the present invention are used as part of a combination treatment regimen, the components of each composition will be administered during a desired treatment period. Whether comprising the two components as separate dosage units or as a single dosage form, the components of the composition may be administered simultaneously during the treatment period, may be administered at different times during the treatment period, or may be administered as a pre-treatment of the other.
As to compounds
The compounds of the invention may be used in therapy in free form or, where appropriate, in the form of a pharmaceutically acceptable salt or other derivative. As used herein, the term "pharmaceutically acceptable salts" refers to organic and inorganic salts of the compounds of the present invention which are suitable for use in humans and lower animals without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts of amines, carboxylic acids, phosphonates, and other types of compounds are well known in the art. The salts can be formed by reacting the isolated and purified compounds of the present invention with a suitable free base or acid.
Pharmaceutically non-toxic acid salts include, but are not limited to, amino salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, or by using methods well known in the art, for example, ion exchange. Other pharmaceutically acceptable salts include adipates, alginates, ascorbates, aspartates, benzenesulfonates, benzoates, bisulfates, borates, butyrates, camphorates, camphorsulfonates, citrates, cyclopentane, digluconates, dodecylsulfates, ethanesulfonates, formates, fumarates, glucoheptonates, glycerophosphates, gluconates, hemisulfates, heptanes, caproates, hydroiodides, 2-hydroxyethanesulfonates, lactobionates, lactates, laurates, lauryl sulfates, malates, maleates, malonates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oleates, oxalates, palmitates, pamoates, pectinates, persulfates, per3-phenylpropionates, phosphates, picrates, pivalates, propionates, stearates, succinates, sulfates, tartrates, thiocyanates, p-toluenesulfonates, undecanoates, valeric acid salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Other pharmaceutically acceptable salts include the appropriate non-toxic ammonium, quaternary ammonium, and amine-based cations formed using such salts as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.
In addition, the term "prodrug" as used herein means that a compound can be converted in vivo to a compound of the present invention represented by formula (I). This conversion is by hydrolysis of the prodrug in the blood or by enzymatic action in the blood or tissue to the parent compound.
Composition comprising a metal oxide and a metal oxide
The compositions described herein consist of any of the compounds (or prodrugs, or pharmaceutically acceptable salts, or other pharmaceutically acceptable derivatives thereof) described herein, and one or more pharmaceutically acceptable carriers or excipients. These compositions may optionally further comprise one or more additional therapeutic agents. The compounds of the invention may be co-administered to a patient in need thereof with one or more other treatment regimens (e.g., administration of Tofacitinib or other kinase inhibitors, interferons, bone marrow transplantation, farnesyl transferase inhibitors, bisphosphonates, thalidomide, cancer vaccines, hormonal therapy, antibodies, radiation, etc.). The pharmaceutical composition of the compound may be another anti-inflammatory or anti-cancer agent or agents.
As described herein, the compositions of the present invention comprise a compound of the present invention in combination with a pharmaceutically acceptable carrier, including any and all solvents, diluents or other vehicles, dispersing or suspending aids, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as appropriate to the particular dosage form desired. Some examples of pharmaceutically acceptable carrier materials include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; tragacanth powder; malt; gelatin; talc powder; excipients, such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; ethylene glycols, such as propylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; ringer's solution; ethanol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants, may also be present in the composition.
Formulation of
The invention also encompasses a class of compositions (collectively referred to herein as "carrier" materials) in which the active compounds of the invention are used in combination with one or more pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and also includes other active ingredients, if desired. The active compounds of the present invention may be administered by any suitable route, preferably in the form of pharmaceutical compositions adapted to such route of administration for the effective dosage required for the intended treatment. The compounds and compositions of the present invention may be administered orally, mucosally, topically, rectally, pulmonarily, e.g., by inhalation spray, or parenterally, including intravascular, intravenous, intraperitoneal, subcutaneous, intramuscular, intrasternal, and infusion techniques. Administration is in the form of a dosage unit-based formulation and contains pharmaceutically acceptable carriers, adjuvants, and excipients. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. Examples of such dosage units are tablets or capsules. For example, they may contain the active ingredient in an amount of from 1 to 2000 mg, preferably from 1 to 500 mg, more usually from 5 to 200 mg. The appropriate daily dosage for a person or other mammal may vary depending on the patient and other factors, but may be determined again using conventional methods. As previously mentioned, the amount of compound in the administration and dosage regimen of the compounds and/or compositions contemplated by the present invention will depend upon a variety of factors including the age, weight, sex and medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, dosage regimens can vary widely, but can be determined using standard methods. Typical daily doses are in the range of from 0.01 to 500 mg/kg body weight, preferably from 0.1 to 125 mg/kg body weight, more preferably from 1 to 25 mg/kg body weight.
The active compounds of the invention are generally combined with one or more adjuvants, excipients or carriers to form the route of administration. If administered orally, the compounds may be mixed with lactose, sucrose, starch powder, cellulose alkanoates, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia, sodium alginate, polyvinylpyrrolidone and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled release formulation provided by dispersing the active compound in hydroxypropylmethyl cellulose. Formulations suitable for topical administration include liquid or semi-liquid formulations suitable for penetration through the skin (e.g. liniments, lotions, ointments, creams or pastes) and drops suitable for administration to the eye, ear or nose. Suitable topical dosages of the compounds of the invention are 0.1 to 150mg, one to four times daily, preferably 1 to 2 times daily. For topical administration, where an ointment is used, the active ingredient may be combined with any paraffin or water-miscible ointment as the base. Alternatively, the active ingredient may be formulated as a water-in-oil emulsion base cream. If desired, the aqueous phase of the cream base may include, for example, at least 30% by weight of a polyhydric alcohol such as propylene glycol, butane-1, 3-diol, mannitol, sorbitol, glycerin, polyethylene glycol, and mixtures thereof. Topical formulations may include compounds that enhance the absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulfoxide and related analogs. The compounds may also be administered by transdermal means. Preferably transdermal administration will be accomplished using a patch containing a reservoir and a porous membrane or solid matrix. The oily phase of the emulsions of the invention may be constituted in a known manner by known ingredients, comprising a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, the hydrophilic emulsifier is used simultaneously with the lipophilic emulsifier as stabilizer, and it is also preferred that it is used in combination with oils and fats. Emulsifiers and emulsion stabilizers suitable for use in the formulations of the present invention include tween 60, span 80, cetearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with an emulsifying wax, or other materials well known in the art. Creams should preferably be non-greasy, non-staining and washable products with a suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono-or dibasic alkyl esters such as diisoadipate, isohexadecyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or mixed branched chain esters may also be used. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils may be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, particularly an aqueous solvent for the active ingredient. The active ingredient is preferably present in these formulations in a concentration of 0.5% to 20% by weight, more advantageously 0.5 to 10% by weight, and most preferably about 1.5% by weight. The formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from one or more sterile powders or granules using the formulations for oral administration mentioned herein or carriers or diluents using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical arts.
The active ingredient may also be administered by injection, in combination with a suitable carrier including saline, dextrose or water, or with cyclodextrin (Captisol), co-solvent solubilisation (i.e. propylene glycol) or micelle solubilisation (i.e. tween 80). The formulations may also be presented as sterile injectable solutions or suspensions in a non-toxic parenterally-acceptable diluent or solvent, for example as 1, 3-butanediol. Solvents which may be used are water, ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Any bland fixed oil may be employed for this purpose including synthetic mono-or diglycerides.
For pulmonary administration, the pharmaceutical compositions may be administered in the form of an aerosol or with an inhaler, including a dry powder aerosol. Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient, such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug. The pharmaceutical compositions may be formulated with conventional pharmaceutical procedures such as sterilization and/or may contain conventional adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, buffers and the like in tablets and pills or may be formulated with enteric coatings. Such compositions may also contain adjuvants such as wetting agents, sweetening, flavoring and perfuming agents.
The pharmaceutical compositions of the invention comprise a compound of structural formula (I) as described herein or a pharmaceutically acceptable salt thereof, a kinase inhibitor (small molecule, polypeptide, antibody, etc.), an immunosuppressive agent, an anticancer agent, an antiviral agent, an anti-inflammatory agent, an antifungal agent, an antibiotic, or an additional active agent that is an anti-vascular hyperproliferative compound; and any pharmaceutically acceptable carrier, adjuvant or vehicle. Alternative compositions of the invention include a compound having formula (I) as described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, adjuvant or vehicle. Such compositions may optionally comprise one or more additional therapeutic agents, including, for example, kinase inhibitors (small molecules, polypeptides, antibodies, etc.), immunosuppressive agents, anti-cancer agents, antiviral agents, anti-inflammatory agents, antifungal agents, antibiotics, or anti-vascular hyperproliferative compounds.
The term "pharmaceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that can be administered to a patient with a compound of the invention, and which does not destroy pharmaceutical activity and is non-toxic at doses sufficient to deliver a therapeutic amount of administration. Pharmaceutically acceptable carriers, adjuvants and excipients may be used in the pharmaceutical compositions of the present invention, including, but not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self Emulsifying Drug Delivery Systems (SEDDS), such as d-atopHenol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms, such as tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, surfactants used in partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and wool fat. Cyclodextrins, such as α -, β -, and γ -cyclodextrins, or chemically modified derivatives such as hydroxyalkyl, including 2 and 3-hydroxypropyl-cyclodextrins, or other solubilized derivatives may also be advantageously employed to enhance delivery of the compounds of the formulae described herein. The pharmaceutical compositions may be administered orally in any acceptable dosage form, including but not limited to capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, for example, are also commonly added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When administered orally using aqueous suspensions and/or emulsions, the active ingredient may be suspended or dissolved in an oily phase with emulsifying and/or suspending agents. If desired, certain sweetening, flavoring and/or coloring agents may be added. The pharmaceutical composition may comprise the use of liposomes or microencapsulation techniques, various examples of which are found in the literature. The pharmaceutical composition may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents, examples of which are also well known in the art.
Combination drug
The compounds of the present invention may be used as such, or in combination with one or more other compounds of the present invention or with one or more other agents. When administered in combination, the therapeutic agents may be formulated for simultaneous administration or for sequential administration at different times, or the therapeutic agents may be administered as a single composition. By "combination therapy" is meant the use of a compound of the invention together with another agent, either by co-administration of each agent simultaneously or by sequential administration of each agent, in either case, for the purpose of achieving optimal efficacy of the drug. Co-administration includes simultaneous delivery dosage forms, as well as separate dosage forms for each compound. Thus, administration of the compounds of the invention may be used concurrently with other therapies known in the art, for example, radiation therapy or adjunctive therapies such as cytostatics, cytotoxic agents, other anti-cancer agents, etc. in the treatment of cancer to ameliorate the symptoms of the cancer. The present invention is not limited to the order of administration; the compounds of the invention may be administered previously, concurrently, or after other anti-cancer or cytotoxic agents.
While the foregoing is directed to the preferred embodiment of the present invention, it will be understood by those skilled in the art that various changes and modifications may be made in the embodiment of the invention without departing from the spirit and scope of the invention.
Claims (10)
1. A compound, or a pharmaceutically acceptable salt thereof, having the structural formula (I):
wherein,
R 3 is a) a hydrogen, hydroxy, cyano,
b)C 1 -C 5 a straight-chain or branched alkyl group,
c)C 3 -C 7 a cycloalkyl group, which is a cyclic alkyl group,
d)C 1 -C 5 a straight-chain or branched alkoxy group, or a linear or branched alkoxy group,
e)C 1 -C 5 a straight-chain or branched alkylthio group,
f) A 5-7 membered heterocyclic ring, said 5-7 membered heterocyclic ring containing 1-2 heteroatoms selected from O and/or N and/or S, when the heteroatom is N, the N is attached acetyl or propionyl;
R 6 is composed of
c)C 1 -C 5 A straight-chain or branched alkyl group,
2. a compound, or a pharmaceutically acceptable salt thereof, having the structural formula (I):
wherein,
R 3 is R 22 Substituted C 1 -C 3 Alkoxy radical, R 22 Is hydroxy, C 1 -C 3 Alkoxy, hydroxy-substituted C 1 -C 3 An alkoxy group;
R 6 is C) C 1 -C 5 A linear or branched alkyl group, or
3. A compound, or a pharmaceutically acceptable salt thereof, selected from:
4- [ (5-hydroxypentyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (5-methoxypentyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (3-hydroxy-3-methylbutyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ [ (1-acetylpiperidin-4-yl) methyl ] amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ [2- (1-acetylpiperidin-4-yl) ethyl ] amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4-n-butylamino-2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
2- [ (1-methyl-1H-pyrazol-4-yl) amino ] -4- (n-pentylamino) pyrimidine-5-carboxamide;
4-isobutylamino-2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
2- [ (1-methyl-1H-pyrazol-4-yl) amino ] -4-neopentylaminopyrimidine-5-carboxamide;
4- (isopentylamino) -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (3, 3-dimethylbutyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
2- [ (1-methyl-1H-pyrazol-4-yl) amino ] -4- [ (4-methylpentyl) amino) pyrimidine-5-carboxamide;
2- [ (1-methyl-1H-pyrazol-4-yl) amino ] -4- (heptylamino) pyrimidine-5-carboxamide;
4- [ (cyanomethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (2-cyanoethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (2-hydroxyethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (2-methoxyethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (3-methoxypropyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (cyclopropylmethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (cyclobutylmethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (cyclopentylmethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (cyclohexylmethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
2- [ (1-methyl-1H-pyrazol-4-yl) amino ] -4- [ [ (tetrahydro-2H-pyran-4-yl) methyl ] amino ] pyrimidine-5-carboxamide;
4- [ (2-cyclopropylethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (2-cyclopentylethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
4- [ (2-cyclohexylethyl) amino ] -2- [ (1-methyl-1H-pyrazol-4-yl) amino ] pyrimidine-5-carboxamide;
2- [ (1-methyl-1H-pyrazol-4-yl) amino ] -4- [ [2- (tetrahydro-2H-pyran-4-yl) ethyl ] amino ] pyrimidine-5-carboxamide.
4. A compound, or a pharmaceutically acceptable salt thereof, selected from:
2- ((1-tert-butyl-1H-pyrazol-4-yl) amino) -4- (isopentylamino) pyrimidine-5-carboxamide;
4- (isopentylamino) -2- ((1- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) amino) pyrimidine-5-carboxamide;
2- ((1-tert-butyl-1H-pyrazol-4-yl) amino) -4- ((2- (2-hydroxyethoxy) ethyl) amino) pyrimidine-5-carboxamide;
4- ((2- (2-hydroxyethoxy) ethyl) amino) -2- ((1- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) amino) pyrimidine-5-carboxamide;
2- ((1-tert-butyl-1H-pyrazol-4-yl) amino) -4- ((2- (2-methoxyethoxy) ethyl) amino) pyrimidine-5-carboxamide;
4- ((2- (2-methoxyethoxy) ethyl) amino) -2- ((1- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-4-yl) amino) pyrimidine-5-carboxamide;
2- ((1-tert-butyl-1H-pyrazol-4-yl) amino) -4- ((2- (2- (2-hydroxyethoxy) ethoxy) ethyl) amino) pyrimidine-5-carboxamide.
5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the salt is selected from: malate, hydrochloride, sulfate, methanesulfonate, formate, acetate, citrate, tartrate, fumarate, gluconate, oxalate.
6. A pharmaceutical composition consisting of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 4 and a pharmaceutically acceptable carrier or excipient.
7. A pharmaceutical composition comprising: comprising as active ingredient a compound of formula (I) as defined in any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, one or more further therapeutic agents, and one or more pharmaceutically acceptable carriers or excipients.
8. Use of a compound of formula (I) according to any one of claims 1-4 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of autoimmune diseases associated with the tyrosine kinases JAK1, JAK2, JAK3, TYK2 and cancer, wherein the diseases comprise: fundus disease, dry eye, psoriasis, vitiligo, dermatitis, alopecia areata, rheumatoid arthritis, colitis, multiple sclerosis, systemic lupus erythematosus, crohn's disease, atheroma, pulmonary fibrosis, hepatic fibrosis, myelofibrosis, non-small cell lung cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, ovarian cancer, cervical cancer, colorectal cancer, melanoma, endometrial cancer, prostate cancer, bladder cancer, leukemia, gastric cancer, liver cancer, gastrointestinal stromal tumor, thyroid cancer, nasopharyngeal cancer, esophageal cancer, brain tumor, lymphoma, multiple myeloma, biliary tract cancer sarcoma, bile duct cancer.
9. The use of claim 8, wherein the leukemia comprises chronic myelogenous leukemia or acute myelogenous leukemia.
10. The use of claim 8, wherein the lymphoma comprises non-Hodgkin's lymphoma, B-cell or T-cell lymphoma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710856218 | 2017-09-21 | ||
CN2017108562180 | 2017-09-21 | ||
CN201811099717.0A CN109535132B (en) | 2017-09-21 | 2018-09-20 | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811099717.0A Division CN109535132B (en) | 2017-09-21 | 2018-09-20 | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113214230A CN113214230A (en) | 2021-08-06 |
CN113214230B true CN113214230B (en) | 2022-10-04 |
Family
ID=65841398
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110684506.9A Active CN113214230B (en) | 2017-09-21 | 2018-09-20 | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof |
CN201811099717.0A Active CN109535132B (en) | 2017-09-21 | 2018-09-20 | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811099717.0A Active CN109535132B (en) | 2017-09-21 | 2018-09-20 | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN113214230B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS64755B1 (en) * | 2019-05-10 | 2023-11-30 | Deciphera Pharmaceuticals Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
KR20220008873A (en) | 2019-05-10 | 2022-01-21 | 데시페라 파마슈티칼스, 엘엘씨. | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103781780A (en) * | 2011-07-28 | 2014-05-07 | 赛尔佐姆有限公司 | Heterocyclyl pyrimidine analogues as JAK inhibitors |
CN104169272A (en) * | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101218229A (en) * | 2005-05-05 | 2008-07-09 | 阿斯利康(瑞典)有限公司 | Pyrazolyl-amino-substituted pyrimidines and their use in the treatment of cancer |
CN105218523B (en) * | 2015-09-18 | 2019-08-23 | 上海吉铠医药科技有限公司 | Pyridine derivate PIM kinase inhibitor and preparation method thereof and the application in pharmacy |
CN105418616B (en) * | 2015-12-26 | 2018-01-12 | 山东大学 | A kind of JAK kinase inhibitors containing 4 amino-pyrazol structures and its preparation method and application |
-
2018
- 2018-09-20 CN CN202110684506.9A patent/CN113214230B/en active Active
- 2018-09-20 CN CN201811099717.0A patent/CN109535132B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103781780A (en) * | 2011-07-28 | 2014-05-07 | 赛尔佐姆有限公司 | Heterocyclyl pyrimidine analogues as JAK inhibitors |
CN104169272A (en) * | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CN109535132A (en) | 2019-03-29 |
CN113214230A (en) | 2021-08-06 |
CN109535132B (en) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE48731E1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
EP3584239B1 (en) | O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof | |
KR101686685B1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
JP2024037954A (en) | RIP1 inhibitory compounds and methods for making and using the same | |
CN108366994B (en) | Novel selective inhibitors of Jak1 and uses thereof | |
JP7395730B2 (en) | Heterocyclic RIP1 inhibitory compounds | |
CN108503650B (en) | Dioxane and quinazoline compound or medicinal salt or hydrate thereof and application of dioxane and quinazoline compound or medicinal salt or hydrate thereof as tyrosine kinase inhibitor | |
WO2014082578A1 (en) | Heteroaryl alkyne compound and application thereof | |
JP2021050231A (en) | Crystalline fgfr4 inhibitor compound and uses thereof | |
JP6916562B2 (en) | Compounds, pharmaceutically acceptable salts thereof, solvates, stereoisomers and tautomers, and drug compositions, hyperproliferative disorder therapeutic agents, hyperproliferative disorder prophylaxis agents, drugs, cancer therapeutic agents, cancer Prophylactic agents and kinase signaling regulators | |
JP7251841B2 (en) | Aromatic ring-bonded dioxino-quinazoline or dioxino-quinoline compounds, compositions and uses thereof | |
TW201422616A (en) | Substituted pyridopyrazines as Syk inhibitors | |
KR20190035755A (en) | Heterocyclic compounds as JAK inhibitors, and salts thereof and therapeutic uses | |
CN113214230B (en) | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | |
TWI828289B (en) | Compounds as TYK2/JAK1 pseudokinase domain inhibitors and methods of synthesis and use | |
JP2008525461A (en) | Selective inhibitor of ERK protein kinase and use thereof | |
JP7117029B2 (en) | 2-Substituted pyrazoleamino-4-substituted amino-5-pyrimidineformamide compounds, compositions and uses thereof | |
KR20210142553A (en) | Pharmaceutical composition for preventing or treating small cell lung cancer associated with ron mutation and method using the same | |
EP4154890A1 (en) | Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same | |
CN110734427B (en) | Alkenyl-containing pyrimidine formamide compound, composition and application thereof | |
US10584121B2 (en) | Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof | |
TWI847289B (en) | Quinazoline compounds, compositions and applications thereof | |
CN110862398B (en) | Urea substituted aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof | |
CN117357650A (en) | Pharmaceutical composition comprising SOS1 inhibitor | |
CN102336740B (en) | Novel imidazole compound and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |